Decoding empagliflozin’s molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence

Decoding empagliflozin’s molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence

Abstract The use of sodium-glucose co-transporter 2 inhibitors to treat heart failure with preserved ejection fraction (HFpEF) is under investigation in ongoing clinical trials, but the exact mechanism of action is unclear. Here we aimed to use artificial intelligence (AI) to characterize the mechan...

Full description

Bibliographic Details
Main Authors: Antoni Bayes-Genis, Oriol Iborra-Egea, Giosafat Spitaleri, Mar Domingo, Elena Revuelta-López, Pau Codina, Germán Cediel, Evelyn Santiago-Vacas, Adriana Cserkóová, Domingo Pascual-Figal, Julio Núñez, Josep Lupón
Format: Article
Language:English
Published: Nature Publishing Group 2021-06-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-91546-z

Internet

https://doi.org/10.1038/s41598-021-91546-z

Similar Items